Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28227903 | 0.83 | LMNA (0.63) | LMNAKDM4ECHRM1ALDH1A1P2RX4 | |
| SCHEMBL6313804 | 0.82 | LMNA (0.62) | LMNAKDM4ECHRM1ALDH1A1P2RX4 | |
| SCHEMBL19668173 | 0.80 | LMNA (0.56) | LMNAKDM4ECHRM1ALDH1A1 | |
| SCHEMBL30747701 | 0.79 | LMNA (0.59) | LMNAKDM4ECHRM1ALDH1A1P2RX4 | |
| SCHEMBL398161 | 0.79 | POLB (0.61) | LMNAKDM4EALDH1A1 | |
| SCHEMBL28274592 | 0.79 | LMNA (0.59) | LMNAKDM4ECHRM1ALDH1A1P2RX4 | |
| SCHEMBL30421484 | 0.79 | POLB (0.61) | LMNAKDM4EALDH1A1 | |
| SCHEMBL7545236 | 0.79 | LMNA (0.59) | LMNAKDM4ECHRM1ALDH1A1P2RX4 | |
| SCHEMBL10665262 | 0.79 | KDM4E (0.42) | LMNAKDM4EALDH1A1 | |
| SCHEMBL30309433 | 0.78 | KDM4E (0.61) | LMNAKDM4ECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309565-B1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-6878704-B2 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1309565-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | LMNA 2120/4885KDM4E 4142/4885CHRM1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.